News

Liquidia’s LIQ861 Safe and Effective in PAH Patients, Phase 3 Trial Suggests

A Phase 3 clinical trial testing LIQ861 met its primary objective, showing that the investigational inhaled dry powder treprostinil formulation is safe and effective for the treatment of pulmonary arterial hypertension (PAH), according to clinical biopharmaceutical company Liquidia Technologies. Liquidia’s LIQ861 is an alternative to the current inhaled treprostinil treatment…

Transition from PDE5i to Adempas Without Washout Period Deemed Safe

Transition from phosphodiesterase-5 inhibitors (PDE5i) — such as United Therapeutics’ Adcirca (taladafil) and Pfizer‘s Revatio (sildenafil) — to Bayer‘s Adempas (riociguat), a soluble guanylate cyclase (sGC) stimulator, without a washout period is a viable option for some patients with pulmonary hypertension, a small study suggests. The…